Cibus, Inc. Logo

Cibus, Inc.

Develops & licenses gene-edited, non-transgenic traits to the seed industry for resilient crops.

CBUS | US

Overview

Corporate Details

ISIN(s):
US13173L1070 (+1 more)
LEI:
Country:
United States of America
Address:
6455 NANCY RIDGE DRIVE, 92121 SAN DIEGO
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Cibus, Inc. is an agricultural biotechnology company that develops and licenses plant traits to the seed industry. The company utilizes a proprietary, high-throughput precision gene-editing technology to create specific, value-added traits in a non-transgenic manner, significantly accelerating the development timeline compared to traditional breeding. Cibus focuses on creating more resilient and sustainable crops by developing traits that provide herbicide tolerance, disease resistance, and pest resistance. Its business model involves partnering with seed companies to integrate these traits into major crops like canola, soybean, and wheat, generating revenue through licensing agreements and royalties.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cibus, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cibus, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cibus, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea
153710
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea
476040
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX
OXFORD BIODYNAMICS PLC Logo
Develops precision blood tests using 3D genomics for cancer diagnosis and therapy guidance.
United Kingdom
OBD
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium
OXUR
Pasithea Therapeutics Corp. Logo
Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.
United States of America
KTTA

Talk to a Data Expert

Have a question? We'll get back to you promptly.